Cover Image
市場調查報告書

Helsinn Healthcare S.A.:產品平台分析

Helsinn Healthcare S.A. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 199699
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
Helsinn Healthcare S.A.:產品平台分析 Helsinn Healthcare S.A. - Product Pipeline Review - 2014
出版日期: 2014年06月15日 內容資訊: 英文 41 Pages
簡介

本報告提供Helsinn Healthcare S.A.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Helsinn Healthcare S.A.的基本資料

Helsinn Healthcare S.A.概要

  • 主要資訊
  • 企業資料

Helsinn Healthcare S.A.:R&D概要

  • 主要的治療範圍

Helsinn Healthcare S.A.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Helsinn Healthcare S.A.:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Helsinn Healthcare S.A.:藥物簡介

  • (netupitant + palonosetron)
  • anamorelin hydrochloride
  • ATH-008
  • elsiglutide
  • ipamorelin等

Helsinn Healthcare S.A.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Helsinn Healthcare S.A.:最近的開發平台趨勢

Helsinn Healthcare S.A.:暫停中的計劃

Helsinn Healthcare S.A.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • becatecarin

Helsinn Healthcare S.A.:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04986CDB

Global Markets Direct's, 'Helsinn Healthcare S.A. - Product Pipeline Review - 2014', provides an overview of the Helsinn Healthcare S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Helsinn Healthcare S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Helsinn Healthcare S.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Helsinn Healthcare S.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Helsinn Healthcare S.A.'s pipeline products

Reasons to buy

  • Evaluate Helsinn Healthcare S.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Helsinn Healthcare S.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Helsinn Healthcare S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Helsinn Healthcare S.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Helsinn Healthcare S.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Helsinn Healthcare S.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Helsinn Healthcare S.A. Snapshot
    • Helsinn Healthcare S.A. Overview
    • Key Information
    • Key Facts
  • Helsinn Healthcare S.A. - Research and Development Overview
    • Key Therapeutic Areas
  • Helsinn Healthcare S.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Helsinn Healthcare S.A. - Pipeline Products Glance
    • Helsinn Healthcare S.A. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Helsinn Healthcare S.A. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Helsinn Healthcare S.A. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Helsinn Healthcare S.A. - Drug Profiles
    • (netupitant + palonosetron)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • anamorelin hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATH-008
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • elsiglutide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ipamorelin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Agonize Ghrelin Receptor for Cancer Cachexia and Anorexia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize Ghrelin Receptor for Gastric Disorder
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize Ghrelin Receptor for Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inverse Agonize Ghrelin Receptor for Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Helsinn Healthcare S.A. - Pipeline Analysis
    • Helsinn Healthcare S.A. - Pipeline Products by Target
    • Helsinn Healthcare S.A. - Pipeline Products by Route of Administration
    • Helsinn Healthcare S.A. - Pipeline Products by Molecule Type
    • Helsinn Healthcare S.A. - Pipeline Products by Mechanism of Action
  • Helsinn Healthcare S.A. - Recent Pipeline Updates
  • Helsinn Healthcare S.A. - Dormant Projects
  • Helsinn Healthcare S.A. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • becatecarin
  • Helsinn Healthcare S.A. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Helsinn Healthcare S.A., Key Information
  • Helsinn Healthcare S.A., Key Facts
  • Helsinn Healthcare S.A. - Pipeline by Indication, 2014
  • Helsinn Healthcare S.A. - Pipeline by Stage of Development, 2014
  • Helsinn Healthcare S.A. - Monotherapy Products in Pipeline, 2014
  • Helsinn Healthcare S.A. - Combination Treatment Modalities in Pipeline, 2014
  • Helsinn Healthcare S.A. - Pre-Registration, 2014
  • Helsinn Healthcare S.A. - Phase III, 2014
  • Helsinn Healthcare S.A. - Phase II, 2014
  • Helsinn Healthcare S.A. - Preclinical, 2014
  • Helsinn Healthcare S.A. - Discovery, 2014
  • Helsinn Healthcare S.A. - Pipeline by Target, 2014
  • Helsinn Healthcare S.A. - Pipeline by Route of Administration, 2014
  • Helsinn Healthcare S.A. - Pipeline by Molecule Type, 2014
  • Helsinn Healthcare S.A. - Pipeline Products by Mechanism of Action, 2014
  • Helsinn Healthcare S.A. - Recent Pipeline Updates, 2014
  • Helsinn Healthcare S.A. - Dormant Developmental Projects,2014
  • Helsinn Healthcare S.A. - Discontinued Pipeline Products, 2014

List of Figures

  • Helsinn Healthcare S.A. - Pipeline by Top 10 Indication, 2014
  • Helsinn Healthcare S.A. - Pipeline by Stage of Development, 2014
  • Helsinn Healthcare S.A. - Monotherapy Products in Pipeline, 2014
  • Helsinn Healthcare S.A. - Combination Treatment Modalities in Pipeline, 2014
  • Helsinn Healthcare S.A. - Pipeline by Top 10 Target, 2014
  • Helsinn Healthcare S.A. - Pipeline by Top 10 Route of Administration, 2014
  • Helsinn Healthcare S.A. - Pipeline by Top 10 Molecule Type, 2014
  • Helsinn Healthcare S.A. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top